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ABSTRACT
Proteins can be described as the “machineries” responsible for almost all tasks in the levels
of organizational complexity in multi-cellular organisms namely: the cells, tissues, organs and
systems. Any disorder in the function of a protein at any of these levels could result in disease, and
a study of protein function is critical to understanding the pathological features of the disease at
the molecular level. A quick glance at these abundantly present proteins reveals two striking
features: large diversity of biological function, and the variations in structural complexity, which
varies from simple random coils, to turns and helices, and on to structured assemblies of turns,
helices and sheets.
Over the past few years, more research efforts have been channeled to the application of
synthetic research to protein dynamics, most especially in disease conditions. This provides insight
into the design and development of chemical tools capable of modulating protein functions .Some
of such tools include small molecules, peptides and peptidomimetics.
In this work, we have described the application of these tools to three (3) different disease
systems topping the list of incurable diseases: HIV, Diabetes, and Cancer. We have designed and
developed chemical probes to facilitate a better understanding of major “culprit” proteins
underlying the pathological conditions associated with these diseases. Our designed chemical
probes were capable of modulating protein functions by producing the desired effects: inhibition
of protein-protein interactions.
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CHAPTER 1 : INTRODUCTION
1.1 Peptidomimetics
In the last three decades, peptides have gained a broader application, especially for
therapeutic interventions.1 The relevant application of these macromolecules to nature, and their
facile and well-established solid phase synthesis (SPPS) have encouraged their study, and proven
applicability in medicinal chemistry and drug discovery.2, 3 Even though the solubility of peptides
is strictly sequence-dependent, they generally exhibit better solubility profiles than classical
medicinal chemistry therapeutics, including

low molecular weight compounds and small

molecules.4 Despite their abundance and relative ease of accessibility, their application is limited
by major drawbacks including protease degradation ,poor oral availability, short plasma half-life.1
However, several strategies have been explored to fully or partially address these concerns.
These include backbone modification,5,

6 7

cyclization,8-11 PEGylation,12 lipidation,13,

14

and

stapling.15, 16 Another very effective approach is the concept of peptidomimetics.17
Peptidomimetics are small, protein-like chains that are capable of mimicking native analogs with
presumably better pharmacokinetic and pharmacological profiles.18, 19
1.2 Protein-Protein Interactions (PPIs)
Protein-protein interactions (PPIs) are short-lived interactions between protein partners.
The driving force for these interactions could be one or more of these: electrostatic and
hydrophobic interactions, hydrogen bonding, and Van der Waals attraction. Compared to enzymesubstrate interactions, the druggability of PPIs is very poor because they lack well defined binding

1

pockets.20 For instance, two proteins can interact with each other over large areas and in a less
defined way as seen in transcription factors and their co-activators.
PPIs form the basis of a wide range of crucial cellular processes, hence, they are
indispensable to human existence.20 An appealing and innovative strategy to drug discovery is the
disruption and destabilization of PPIs. However, this comes with a lot of challenges including
difficulty in screening assays due to lack of measurable output, and poor druggability.21These
bottlenecks have limited research in this area as many small molecules cannot span the entire
length of the interacting flat surfaces in PPIs. In addition, large molecules cannot gain access to
PPIs targets in cell compartments.20 The short-term nature of these interactions also makes
quantitative evaluations difficult.
Due to these challenges, only one small molecule PPI inhibitor have been approved till
date: Venetoclax (Venclexta).22,

23

Venetoclax (Venclexta) is a BH3-mimetic developed by

AbbVie and Genentech,and approved for the treatment of Chronic Lymphocytic Leukaemia
(CLL).This was approved in 2016 and works by inhibiting the interaction between BCL-2,a BH3only protein, and the pro-apoptotic proteins, BAK and BAX. This inhibition results in the apoptosis
of CLL cells bearing the 17p deletion.24
Despite these shortcomings, intensive and vigorous research in finding inhibitors of
protein-protein interactions has provided a ray of hope over the past few years. In fact, the recent
successes recounted in this area has indicated that protein-protein interfaces might be easier to
manipulate than previously thought. These studies unraveled the ‘hotspots’ on protein contact
surfaces and developed compact small molecules that bind tighter and deeper within the contact
surface than the contact atoms of the natural protein partner.25-29High-throughput methods that

2

enhance easy screening and accurate qualitative characterization of protein-protein interactions
have been developed.30-32
The identification of epitopes on the interacting surface of proteins (hotspots) have paved
way for the design of peptides and peptidomimetic inhibitors of protein-protein interactions. In
recent times, Peptide fragments consisting of the contact amino acid residues on partner proteins
have been designed.33 On several occasions, alanine scanning has been used to further detect the
most relevant amino acid in the hotspot.29A similar but more effective approach in identifying
protein-protein interactions modulators is peptidomimetics. Peptidomimetics that mimic the
functional epitope of protein complexes have been developed.34-39
The application of peptides and peptidomimetics has advanced the course of medicinal
chemistry and drug discovery as it unlocks potential agents that could target a broad spectrum of
proteins that are implicated in many pathogenic diseases.
1.3 γ-AApeptides
Over the past two decades, peptidomimetics have found important applications in chemical
biology and drug discovery.19 Our recently developed peptidomimetics, γ-AApeptides are
oligomers of N-acylated-N-aminoethyl amino acids, and are capable of accommodating a second
side chain functional group, in addition to the chiral side chain (Figure 1.1).40 This means that a γAApeptide monomer is similar to a canonical dipeptide residue. In addition to having other
desirable features of a typical peptidomimetic, a unique advantage that γ-AApeptides offer is their
limitless derivatization potential, which is not commonly found in most reported peptidomimetics.

3

Figure 1.1 General structure of α-peptide and γ-AApeptide
1.4 Outline of the Dissertation
In this dissertation, we discuss the design, synthesis, and therapeutic applications of
peptides and our recently developed peptidomimetic scaffold, γ-AApeptides, and its derivatives as
chemical probes for protein interactions in disease conditions.
In chapter 2, we describe the design of a modified peptide that shows great HIV-fusion
inhibitory activity.
In chapter 3, we discuss the design of γ-AApeptide –based small molecule ligands that
inhibit the formation of pancreatic amyloid deposits in Type 2 diabetes mellitus.
In chapter 4, we describe the design of retro-D peptides based on the amyloid forming unit
in amylin, the Type 2 diabetes amyloid. We also evaluated their aggregation propensity and fibril
morphology, and tested their inhibitory activity.
In chapter 5, we describe the design and development of short peptide antagonists of the
MPP8-H3K9me interaction, which is implicated in many cancers.
In chapter 6, we summarize our research findings and gave the future directions of all
studies conducted in this research.
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CHAPTER 2 : SULFONO-Γ-AA MODIFIED PEPTIDES THAT INHIBIT HIV-1 FUSION
2.1 Introduction
The global HIV statistics of 2015 revealed that approximately 36.7 million people
worldwide are living with human immunodeficiency virus (HIV) and over 2.1 million new cases
of HIV infection was recorded1 annually. The envelope glycoprotein of human immunodeficiency
virus type 1 (HIV-1) encoded by the HIV env gene, is a somewhat stable membrane fusion machine
which exists as a trimeric complex (gp160)3. This precursor trimer is proteolytically processed by
furin into gp120 and gp41 heterodimers 2. During the membrane fusion process, gp41 forms a
fusion active six-helix bundle (6-HB) with a hydrophobic pocket 3 4. In this six-helix bundle, the
amino-terminal heptad repeat (N-HR) forms a central trimeric coiled-coil core whereas the trimeric
helical carboxyl terminal repeat (C-HR) wraps around and interact with it in an antiparallel fashion
5

. This six-helix bundle brings into close proximity and facilitates the fusion of the viral and host

cell membranes (Figure 2.1) 6, 7 . The mutual dependence of N-HR and C-HR on each other in the
6-HB formation during viral entry makes them very important targets for fusion inhibitor design.
Indeed, Targeting viral entry and fusion process of enveloped virus remains a very appealing
therapeutic strategy due to its relative accessibility. Potent inhibitors which block these specific
interactions that are mandatory for HIV-1 viral entry, including small molecules8-10, engineered
peptides11, artificially designed peptidomimetics12-15, etc., have been discovered. However,
peptides derived from N-HR mostly show weak inhibitory activity if the design does not promote
trimerization of N-HR peptides

5, 16

efficiently target HIV-1 fusion

17-20

. Only typical N-HR constructs forming stable trimers can
. As a result, C-HR derived peptides have been studied
7

extensively in the therapeutic search for potential fusion inhibitors. Examples include α-helical
peptides such as enfuvirtide (T20) 21, 22 and C34 23-26. Enfuvirtide got market approval as the only
HIV-1 fusion inhibitor for clinical use and works by competitively binding the N-HR thereby
blocking the formation of the six-helical bundle required for fusion. It is very active against various
HIV-1 strains including those resistant to reverse transcriptase and protease inhibitors

22, 27

. It is

similar in design to a segment of C-HR comprising amino acids 127 to 162 of the C-terminal end28
29

. Although T20 has great anti-HIV activity, it is prone to induce drug resistance through

mutations within the N-HR sites. Additionally, its poor bioavailability and large dose requirements
complicate its therapeutic use 30, 31. Similar to T20, C34 also has sequence homology to the C-HR.
Due to a 22-amino acid overlap between T-20 and C34 peptides, HIV-1 has also developed major
mutations for C34 resistance in vitro 31. Meanwhile, its bioavailability was still a concern due to
its canonical peptide backbone.
To overcome the problems posed by T20 and other similar HIV fusion inhibitors, great
efforts have been made to optimize the fusion inhibitors derived from the C-HR helical region of
gp41 to suppress the emergence of resistant strains and increase the in-vivo stability and N-HR
binding affinity

32-34 35

. One approach is to introduce electrostatic constraints into peptides to

improve helicity and antiviral activity profile. This entails the substitution of charged and
hydrophilic amino acids such as glutamic acid (E) and Lysine (K) at i and i+4 positions in the
solvent-accessible site of C34 and its short variants

4, 36-39

. In a six helix bundle, C-HR interact

with N-HR with amino acid residues at their a and d positions of the heptad repeat (Figure
2.1).These residues are known to be critical for molecular recognition between both heptad repeats
while residues at positions b, c, f and g are exposed to the solution and are almost non-crucial for
gp41 C-HR and N-HR interaction6.
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A

B

Figure 2.1 (A) Schematic illustration of the different regions of HIV-1 gp41. N-HR: N Heptad
Repeat, C-HR: C Heptad Repeat, MPER: Membrane Proximal Ectodomain Region, MSD:
Membrane Spanning Domain and. (B) Schematic illustration of the helical wheel of gp41 C-HR.

However, the residues at these positions are very critical for solubility and stability and
they have great effects on the in-vivo activity and druggability of peptide fusion inhibitors. These
engineered electrostatic interactions are helix enhancers and have significantly improved the
solubility, helicity and potency of such derived peptides

4, 36, 37, 40

. An additional approach is to

introduce conformational restraints and substitution with non-proteinogenic amino acids in C-HR
derived peptide mimics. For instance, peptidomimetics with unnatural amino acids and building
blocks have been reported to successfully mimic the molecular interaction between gp41 C-HR
and N-HR

12-15, 29, 33, 34, 41-46

. Peptide mimics that targets gp41 N-HR include D-peptides

15, 17

,

unnatural foldamers 44, 45, and covalently restrained α-helices 13, 14, 46. These peptide mimics have
generated highly potent fusion inhibitors with outstanding in-vivo stability..

9

Sulfono-γ-AApeptides are a sub-class of γ-AApeptides that are oligomers of N-acylatedN-aminoethyl amino acids 47-49. The replacement of carboxylic acids with sulfonyl chlorides in γAApeptides produces sulfono- γ-AApeptides (Figure. 2.2). They have enormous potential in
functional group diversity. Like γ-AApeptides, sulfono- γ-AApeptides are able to display the same
number of side chains as conventional peptides of equal length, endowing them with the ability to
mimic bioactive peptides. As evidenced by their crystal structures, sulfono- γ-AApeptides possess
an intrinsic folding propensity which is most likely a result of the bulkiness of the tertiary
sulfonamide group besides intramolecular hydrogen bonding 50. Their optical analysis by circular
dichroism and 2D-NMR also supports their well-crafted helical conformation50. To explore the
potential of sulfono-γ-AApeptides for their ability to modulate HIV-1 fusion at the cell entry stage,
we designed a few peptides containing sulfono-γ-AA residues. Our previous findings suggested
that replacement of amino acid residues with sulfono-γ-AA residues could retain sequence
helicity51. Thus, we envisioned these sequences were still capable of mimicking gp41.

Figure 2.2 General structures of α-peptide,γ-AApeptides, and Sulfonoγ-AApeptides

Peptide 1 is a 24-residue electrostatically constrained C-HR derived peptide with MT-hook, which
was previously reported to be an active fusion inhibitor33. Thus it was used as the template
sequence for modification (Figure 2.3)

33

. As the initial attempt, we employed a combination of

10

sulfono γ-AA residue substitution and single hydrocarbon stapling to identify three peptides: 2, 3
and 4. 3 and 4 contain a sulfono- γ-AA1 residue at the 22nd position while only 2 and 4 contain
hydrocarbon stapling between residues X at the 4th and 8th position (Figure 2.3).
2.2 Results and Discussion
We first assessed the helicity of the sequences by CD. As shown in Figure 2.4,
interestingly, both 1 and 3 exhibited comparable helical folding propensity with characteristic
minima at both 207 and 222 nm suggesting the existence of probable α-helical conformation. This
suggests that incorporation of sulfono-γ-AA residue did not alter helicity significantly. As
expected, after hydrocarbon stapling, both 2 and 4 clearly showed a significant increase in helicity
compared to their unstapled counterparts, 1 and 3 (Figure 2.4). This is consistent with the previous
findings that i, i+4 hydrocarbon stapling enhances the α-helicity of peptides. 46, 52, 53 These findings
are corroborated by the thermal stability studies (Figure 2.5). 1 and 3 showed similar behavior at
low temperature. However, 3 is more stable than 1 at temperature higher than 42°C. Also, 2
demonstrated increased stability than 4. Overall, hydrocarbon stapling improved the helicity and
thermal stability profiles of 2 and 4

11

Figure 2.3 (A) C-HR derived peptides. Peptide 1 is MT-SC22EK and was first reported in ref. 33
;(B)
The
structure
of
sulfono-γAA1(γK)
(S)-N-((2-aminoethyl)sulfonyl)-N-(2,6diaminohexyl)glycine and , (S)-2-(4-pentenyl)Ala residue (X) substituted at i and i+4 positions.
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Figure 2.4 CD spectra of peptides 1 – 4
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Figure 2.5 Melting curve of peptides 1-4

We next examined the antiviral activity of these sulfono-γ-AA containing peptides by viral
infection assay54. Conformationally stabilized pre-formed recombinant env trimers derived from
various subtypes of HIV-1 strains 55 were used in the assay. Both (enfuvirtide) T20 and AZT were
13

also tested for comparison. Intriguingly, both 3 and 4 displayed more potent antiviral activity in
most tested subtypes including CZA97, B41, BG505, SF162 and DU422 than the unsubstituted
peptide 1(control) and stapled peptide 2.This indicates that the introduction of the peptidomimetic
monomer, sulfono- γ-AA1, improved the interaction of peptide 3 and 4 with the N-HR of gp41,
resulting in the inhibition of six-helical bundle formation. It is noteworthy that antiviral activity is
not strictly dependent on secondary structures as evidenced by the obtained results (Table 2.1), as
3 and 4 exhibited comparable antiviral activity All tested peptides showed comparable or greater
anti-HIV activity than enfuvirtide (T20), a fusion inhibitor and AZT, a reverse transcriptase
inhibitor which are currently being used in the clinics for the treatment of the symptomatic disease
(Table 2.1). Thus, 3 and 4 emerged to be the most active with the best antiviral activity across all
strains tested.
Table 2.1 Antiviral activity from Viral infection assay
IC50 (nM) CZA97

B41

BG505

SF162

MN

DU422

1

6.8±1.6

181.1±89.1 15.2±0.2

11.3±2.2

102.4±29.9 14.8±0.3

2

7.6±1.0

210.8±58.9 14.0±0.5

15.6±0.9

67.1±9.1

16.0±1.1

3

4.6±0.1

118.8±4.0

9.0±0.2

7.2±1.8

77.9±2.4

6.0±2.7

4

6.5±0.8

171.3±4.6

9.7±2.6

11.4±0.8

51.2±10.2

11.3±0.1

T20

941.0±328.3 214.6±16.2 18.4±10.1

23.9±2.1

6.5±0.6

56.0±1.6

AZT

184.6±26.4

109.6±23.5 194.1±1.6

106.4±16.8 84.0±1.8

183.3±1.9

To directly interrogate the effect of sulfono-γAA1 substitution and hydrocarbon stapling
on proteolytic cleavage, we used LC/MS to identify proteolytic fragments generated by the
digestion of our peptide panels with chymotrypsin (Figure 2.6). After 10 mins, 2 and 4
14

demonstrated greater stability to chymotrypsin than 1 and 3, suggesting stapling lead to sequences
with increased stability. It is noted that 1 proved better than 3 (Figure 2.6 and Table 2.2), which
may be because the inclusion of sulfono-γ-AA residue slightly altered the helicity, making it easier
to be hydrolyzed. However, after backbone stapling, still possessing one sulfono-γ-AA residue, 4
exhibited almost similar resistance to proteolytic degradation as 1, indicating that the introduction
of unnatural residue could enhance stability of the sequence.
Table 2.2 Enzymatic hydrolysis assay with chymotrypsin
Peptide

% remaining after 10 mins

1

53.3

2

69.3

3

17.6

4

57.2

Figure 2.6 The degradation curves of 1-4

15

2.3 Conclusion
To summarize, although the daunting challenges hampering the clinical applications of
enfuvirtide (T20) has limited the repository of active peptide-fusion inhibitors, the possibility of
incorporating non-natural scaffolds may ultimately usher in new generation of peptide –fusion
inhibitors with great therapeutic potential and improved protease resistance. Although our current
design did not yield peptides with enhanced stability toward proteolysis, our study reveals that
sulfono-γ-AA modified peptides could be used for the development of more potent anti-HIV
agents. Furthermore, it is known that homogeneous sulfono-γ-AApeptides are completely resistant
to enzymatic degradation and they possess remarkable helical propensity, we envision that we
could use homogeneous sulfono-γ-AApeptides to design GP41 mimetics in the future.
Additionally, the strategy implemented herein not only provide ideas for future HIV-1 inhibitor
design, but may also be explored for the protein-protein interaction inhibitor (PPII) design.
2.4 General Information
Peptide Synthesis
All peptides used in this study were synthesized by the standard Fmoc-based solid phase
peptide synthesis protocol using the Burrell Wrist-Action shaker. All Fmoc protected α-amino
acids and Rink amide resin (0.7mmol/g, 200-400 mesh) were purchased from Chem-Impex
International, Inc. All other Solvents and reagents were purchased from either Sigma Aldrich or
Fisher Scientific and used without further purification. The peptides were analyzed and purified
on a Waters Breeze 2 HPLC System, and then lyophilized on a Labconco Lyophilizer
Synthesis of sulfono- γ-AApeptides
Synthesis of Cbz-aminoethanesulfonyl chloride
Taurine (5g) and NaOH (2.5 eq) were dissolved in water and was kept stirring at
0°C.Benzylchloroformate (5.8 eq) was mixed with Dioxane and added dropwise to the solution.
The ice bath was then removed and the reaction was stirred for 1h. The solution was washed with
16

EtOAc three times. The aqueous layer was co-evaporated with Toluene (2 times), Ethanol (once)
and DCM (3 times).The resulting white solid, Cbz-protected aminoethane sodium sulfonate was
suspended in EtOAc and filtered. To the white solid, Thionyl Chloride (10eq) and DMF (3 drops)
were added and the reaction was refluxed for three hours and then concentrated on rotavap to
obtain the Cbz-protected aminoethanesulfonyl chloride (Figure 2.7).

Figure 2.7 Synthesis of Cbz-aminoethanesulfonylchloride
Synthesis of Fmoc-sulfono-γ-AA1
Fmoc-Lysine amino aldehyde and Glycine benzyl ester were dissolved in methanol.
Triethylamine was added and the reaction was stirred for one hour. Sodium cyanoborohydride was
then added to the reaction and left to stir for another hour. The solution was concentrated, extracted
with EtOAc and further concentrated on the rotavap. The crude secondary amine was purified on
silica gel with Hexanes/EtOAc (1:1) as eluent. After that, the secondary amine was dissolved in
DCM, to which Cbz-protected aminoethanesulfonylchloride and DIPEA were added. The reaction
was stirred overnight and the resulting product was purified on silica gel (eluent was
hexanes/EtOAc 2:1). Next, hydrogenation was done in methanol and under hydrogen with 20%
Pd-C for 1 h to remove the benzyl and carbamate group to yield the mono-Boc protected Fmocsulfono- γ-AA1. Boc protection of the amino group on the sulfonyl side chain was achieved by
adding Boc anhydride in THF to a stirred solution of Fmoc-sulfono- γ-AA1 (Boc) and NaHCO3
in water in a dropwise manner. The reaction was allowed to continue overnight at room
temperature. 1N citric acid was added, followed by extraction with EtOAc and drying over
17

Na2SO4.The solution was then concentrated and purified on silica gel. The product, Fmoc-sulfonoγ-AA1 was eluted with Hexanes/EtOAc 1:1 to give a white solid (Figure 2.8).

Figure 2.8 Synthesis of Fmoc-sulfono-γ-AA1.
Solid Phase synthesis.
The synthesis was conducted on 200 mg Rink amide resin (0.7 mmol/g) at room
temperature and atmospheric pressure. The Fmoc protecting group was removed by treatment with
3mL 20% Piperidine in DMF solution for 15 mins(x2).The resin was washed with DCM and DMF
(three times each).A solution of Fmoc-aa-OH/ Fmoc-sulfono- γ-AA1/ Fmoc-(S)-2-(4pentenyl)Ala-OH (2 eq),HOBt (4 eq) and DIC (4 eq) was first premixed in 2mL DMF and then
transferred into the peptide vessel containing the deprotected resin. The mixture was allowed to
shake for 4h. The resin is then washed with DCM and DMF (3x each) and capped with acetic
anhydride (1mL) and Pyridine (2mL) for another 15 min. After capping, deprotection was done
and the cycle was repeated until the desired product was obtained (Figure 2.9).
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Figure 2.9 Solid phase synthesis of stapled peptides.

Olefin Metathesis and Purification.
Ring-closing metathesis (RCM) of resin-bound N-Fmoc, side chain protected peptides was
performed using 20 mol% of Grubbs I catalyst in degassed DCE for 2 hours at room temperature.
The resin-bound peptide was washed in the peptide vessel and filtered. The RCM reaction was
repeated once again to complete the cross-linking reaction. The reaction was monitored by LC/MS
after cleavage of peptide from an aliquot of resin. The resulting stapled peptide was deprotected
and cleaved from the resin with a cleavage cocktail mixture of TFA/Phenol/H2O/thioanisole/1, 2ethanedithiol (82.5%/5% /5% / 5%/2.5% v/v) for 3h and then precipitated with diethyl ether. The
crude peptides(stapled and unstapled) were analyzed and purified on an analytical(1mL/min) and
a preparative (16mL/min) RP-HPLC respectively.5% to 100% linear gradient of solvent B(0.1%
TFA in acetonitrile) in A(0.1 % TFA in water) over 40 min was used. The HPLC traces were
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detected at 215nm.The fraction containing the desired peptides/stapled peptide was collected,
confirmed on an Applied Biosystems 4700 Proteomics Analyzer and lyophilized.
Circular Dichroism Analysis.
Circular dichroism (CD) spectra were measured on an Aviv 215 circular dichroism
spectrometer using a 1 nm bandwidth and 1nm step resolution from 200 to 260nm at 25°C.3 scans
were averaged for each sample. Peptide solutions were prepared in water to a final concentration
of 300µM.The samples were loaded in a 1mm path length quartz cell, and the CD spectra were
acquired with an averaging time of 1s; Settling time of 0.333s and multi-scan wait time of 1s. The
final spectra were normalized by subtracting the average blank spectra. The data unit was
converted from machine units (millidegree,θ) into mean residue ellipticity [θ].Mean Residue
Ellipticity [θ] (deg.cm2.dmol-1) was calculated using the equation:
[θ] = θobs / (p x c x 10 x n)

(i)

Where θobs is the measured ellipticity in millidegrees, while p is the path length in centimeter, n is
the number of side chains and c is the concentration of the peptide in Molar.
The temperature-dependent unfolding was carried out by monitoring the change in ellipticity [θ]
at 222nm at increasing temperature (5-70°C) after 1.6 mins equilibration at the desired temperature
and an integration time of 1s.The temperature was increased at the rate of 1°C per min; data
acquisition was done with the following parameters: 1-nm bandwidth; λ = 222nm
HIV-1 Neutralization Assay.
The preparation of Env-pseudotyped virus stocks in 293T cells by calcium phosphate
transfection and the use of the engineered HIV-1 coreceptor-bearing cell line U87-CD4+-CCR5+
(3,000 cells per well) for Env-pseudotyped virion infection were described previously.56, 57 Briefly,
the envelope genes were amplified by PCR, cloned into an expression vector and cotransfected
20

with an envelope-defective proviral plasmid to generate pseudotyped luciferase-encoding viruses.
Recombinant viruses were used to infect U87-CD4+-CCR5+ cells (3,000 cells per well) in the
presence of varying concentrations of peptide. The amount of input pseudovirus was normalized
by infectivity (virus titer) rather than by p24 antigen content. Luciferase activity in the target cells
was measured in relative light units (RLU) 72 h after infection. Data from duplicate measurements
were fit to the variable-slope-sigmoid equation to obtain IC50 values.54
Protease Stability Assay.
To evaluate the stability of the peptides against enzyme degradation, the peptides (0.1
mg/ml) were incubated with Chymotrypsin (0.1mg/ml) in 100mM pH 7.8 ammonium bicarbonate
buffer for 30 mins. The residual substrate and digested products were quantified by LC-based
peak detection at 280nm. Each experiment was done in duplicate.
The NMR Spectrum of Fmoc-sulfono-γ-AA1
1

H NMR (400 MHz, CDCl3): δ 7.71-7.75 (t, J = 8.00 Hz, 2H), 7.57 – 7.60 (t, J = 8.00 Hz, 2H),

7.34 - 7.37 (t, J = 4.00 Hz, 2H), 7.28 – 7.3 (d, J = 8.00 Hz, 2H), 7.24 (s, 1H), 5.65 – 5.67 (d, J =
8.00 Hz, 1H), 5.22 – 5.27 (m, J = 8.00 Hz, 1H),4.60 – 4.73 (dd, J = 4.00, 16.00 Hz, 1H), 4.38 –
4.43 (t, J = 12.00 Hz,1H) ,4.33 – 4.35 (d, J = 8.00 Hz, 1H), 4.25 – 4.29 (t, J = 8.00 Hz,1H), 4.18
– 4.21 (t, J = 8.00 Hz,1H), 3.76(s,2H), 3.57 – 3.65 (dd, J = 4.00 Hz, 1H), 3.27 – 3.33 (t, J = 16.00
Hz, 2H),3.20 (s,1H), 3.07 (s,2H), 1.50 (s, 4H), 1.41 (s,18H), 1.25 (s,1H).
C NMR (400MHz, DMSO-d6): δ 156.4, 155.9, 155.7, 144.4, 141.4, 127.9, 127.45, 125.6, 120.5,
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78.4, 77.7, 70.2, 65.7, 65.3, 51.5, 47.2, 40.5, 40.3, 40.1, 39.9, 39.7, 39.5, 39.3, 35.3, 31.8, 29.8,
28.7, 23.2. HRMS (ESI): ([M+H]+) calculated for C35H50N4O10S, 719.3281; found, 719.3336.
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Figure 2.10 1H NMR (400 MHz, CDCl3) and MS of Fmoc-sulfono-γ-AA1

Figure 2.11 13C NMR (400 MHz, DMSO-d6) of Fmoc-sulfono-γ-AA1.
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Table 2.3 HPLC purities and retention time of peptides 1-4
Peptide

Molecular
Mass Purity (based
[M+H]+
HPLC) %
(expected/observed)

on Retention
Time (min)

Yield (%)

1

3125.6431/3125.8845

93.55

19.99

67

2

3118.6494/3118.3872

95.45

21.53

54

3

3147.5702/3147.8384

93.62

19.82

63

4

3140.6007/3140.3728

98.89

20.02

48

0.80

1

AU

0.60
0.40
0.20
0.00
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00

20.00

22.00

24.00
26.00
Minutes

28.00

30.00

32.00

34.00

36.00

38.00

40.00

42.00

44.00

46.00

48.0

44.00

46.00

48.0

0.12

2

0.10
0.08
AU

0.06
0.04
0.02
0.00
-0.02
-0.04
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00

20.00

22.00
Minutes

24.00

26.00

28.00

30.00

32.00

34.00

36.00

38.00

40.00

42.00

40.00

42.00

1.00

AU

0.80

3

0.60
0.40
0.20
0.00
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00

20.00

22.00

24.00
26.00
Minutes

28.00

30.00

32.00

34.00

36.00

38.00

0.40

AU

0.30

4

0.20
0.10
0.00
0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00

20.00

Figure 2.12 HPLC spectra of peptides 1-4
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CHAPTER 3 : Γ-AAPEPTIDES –BASED SMALL MOLECULE LIGANDS THAT
DISAGGREGATE HUMAN ISLET AMYLOID POLYPEPTIDE

3.1 Introduction
The human islet amyloid polypeptide (hIAPP), also known as amylin, is a unique
amyloidogenic precursor peptide, and a critical pathogenic feature of Type II diabetes.
Amylin is co-secreted with insulin by the β-cells of the pancreas, and co-stored in the
secretory granules.1As a matter of fact, there is an overwhelming evidence of the useful
role of soluble amylin in glucose metabolism, however, the insoluble aggregates resulting
from the misfolding of this protein is implicated in type II diabetes.2-4 Just like the amyloid
deposits formed in neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s and
Huntington’s diseases)5 and progressive diseases (e.g., Type II diabetes and cystic
fibrosis)6, 7,amylin aggregates consist of stacked protofilaments, leading to a structural
architecture known as the cross-β structure.8-10 The oligomerization of amylin into amyloid
fibrils has been suggested to be a stepwise process: first, the aggregation of monomers into
colloidal spheres, which stop growing after reaching a uniform diameter ; second, the
association of the spheres to form linear chains of toxic, mature fibrils of pore-like
morphology.8The extent of these oligomerization process is strongly correlated to
pancreatic β-cell dysfunction and death in Type II diabetic patients,11-13 therefore, an
impairment of the initial monomer aggregation process is an appealing therapeutic
approach to diabetes drug discovery and development.

27

So far, there is no treatment for pancreatic amyloidosis, and there is only a few
approved therapeutic strategies for its prevention. Hence, the need for channelling intense
research efforts to the search for potent inhibitors of the process producing these pathogenic
fibrils. In line with this, some inhibitors have been reported including the peptides derived
from the various secondary recognition elements along the amylin peptide chain,14-16
engineered peptides,17-19 constrained peptides20-26,small molecules27,
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and natural

products.29-31Although, many of these inhibitors are specific in their activity, a few of them
have exhibited dual inhibitory activity.31-34
In order to advance the application of peptidomimetics in chemical biology and
drug discovery, we have recently introduced our new class of peptidomimetic scaffold, γAApeptide. γ-AApeptide contain N-acylated-N-aminoethyl amino acid units, and are
derived from γ-PNAs.35Each monomeric unit of the γ-AApeptide is equivalent to a
dipeptide residue in a conventional peptide. This means that they are able to project an
identical number of functional groups as canonical peptides of the equal length.
In our previous work, we reported on a small molecule Aβ40 aggregation inhibitor,
HW-155, which was identified from a peptidomimetic OBOC (one-bead-one-compound)
library.36 HW-155 is a γ-AApeptide35 tetramer with little structural similarity to KLVFF,
the core amyloid-forming unit of Aβ. Inspired by the findings on dual inhibitors, and based
on the fact that HW-155 was from an OBOC library, we hypothesized that HW-155 could
be a non-specific amyloid inhibitor. To critically evaluate this hypothesis, we synthesized
HW-155 and eight (8) analogues (1 - 8), and investigated their ability in preventing the
fibrillation of amylin (hIAPP), and the disruption of preformed hIAPP aggregates. We also

28

examined the effect of HW-155 and its analogues (Figure 3.1) on the toxicity of hIAPP
aggregates towards the cell.

Figure 3.1 Peptide Sequences HW-155, control C1 and 1-8

3.2 Results and Discussion
We have previously reported a γ-AApeptide oligomer, HW-155, as a potent
inhibitor of Aβ aggregation. In this study, we investigated the effectiveness of HW-155 in
the inhibition of amyloid formation by hIAPP1-37.First,we studied the aggregation
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behaviour of hIAPP1-37 in the presence of a 2.5- , 5- , and 10- fold molar excesses of HW155.Time-dependent ThT assay revealed a significantly enhanced fluorescent intensity
with hIAPP1-37 (10µM) alone.
Table 3.1 Percent Inhibition (Based on ThT Fluorescence assay) of HW-155,C1 and 1-8.
Peptides 100µM

50µM

25µM

12.5µM

6.25µM

3.13µM

1.56µM

(%)
1

50.6

67.9

44.1

42.7

54.7

43.2

71.8

2

59.2

49.3

55.0

70.6

49.5

43.3

50.1

3

55.1

55.9

60.0

62.3

54.1

54.1

50.7

4

60.5

64.4

63.6

67.4

67.1

58.2

48.7

5

50.0

56.7

73.2

74.1

67.8

66.5

59.6

6

66.0

65.7

64.5

59.0

59.5

65.8

60.2

7

50.4

58.8

48.1

48.8

51.6

50.5

46.7

8

51.9

48.7

51.7

55.0

57.3

47.0

34.4

HW-155 52.0

51.6

45.8

40.2

44.2

45.6

36.5

-2.3*

-21.9*

-11.9*

0.4

-8.9*

-1.6*

C1

21.1

* no inhibition
Surprisingly,HW-155 was able to prevent hIAPP1-37 aggregation by ~50% at the 2.5-, 5and 10-fold molar excesses tested (Figure 3.10).
Encouraged by this result, we further studied the aggregation formation by hIAPP137

in the presence of equimolar or lesser concentration of HW-155.To our surprise, a

significant reduction in the fluorescent intensity of hIAPP1-37 was observed at these tested
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concentrations of HW-155, even with 0.2-fold molar excess of HW-155.This implies that
HW-155 could not only inhibit Aβ aggregation, but also prevent amyloid formation in
hIAPP1-37.This was further confirmed by the TEM images that were captured (Figure 3.13).
A characteristic feature of amyloidogenic peptides is the presence of fibrillary morphology
under the electron microsope. 37
Inspired by this new development, we sought to pinpoint the role and effect of each
monomeric unit in HW-155 on inhibitory activity. Using HW-155 as a template, we
designed and performed a functional analysis of eight (8) analogues of HW-155 namely
peptides 1-8 (Figure 3.1). In four analogues (1-4), we substituted each of the N-side chains
in HW-155 with an acetyl group, while alanine scanning was performed on the chiral side
chains (5-8).We also designed a control peptide, C1, which consists of both modifications.
Our intention was to carefully evaluate the effects of a change in the molecular interface
of HW-155 on inhibition.
Amyloid aggregation kinetics of hIAPP1-37 in the presence of 1-8 was monitored by
time-dependent ThT assay. In an initial attempt, we studied the anti-aggregation activity of
2.5-, 5-, and 10-fold molar excesses of 1-8. Interestingly, peptides 1-8 were able to suppress
the fluorescence by over 40% at 2.5-fold and over 50% at 5- and 10-fold molar excesses.
Further investigation of equimolar of lesser concentrations of 1-8 resulted in a minimum
inhibitory activity of 30% (Figures 3.2 – 3.10).
We identified peptides 3, 5, and 6 (Figures 3.4, 3.6, and 3.7) with over 50%
inhibition across all molar equivalents tested. In fact, 5 (Figure 3.6) showed more than 65%
inhibition at 1-, 0.6- and 0.3-fold molar excesses. Also, our control peptide, C1, only
prevented hIAPP1-37 aggregation at a 10-fold molar excess (Table 3.1).
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To evaluate the ability of our designed analogues to disaggregate preformed
hIAPP1-37 fibrils, we performed a time – dependent ThT assay and monitored the
fluorescent intensity for over twenty four (24) hours. Interestingly, only 5 was able to
disrupt preformed hIAPP1-37 fibrils at a tested concentration of 100µM (Figure 3.11).
Further evidence of hIAPP1-37 aggregation inhibition by the designed analogues and
HW-155 was obtained from the TEM morphological studies of hIAPP1-37 that was preincubated with equimolar amount of peptides 2,3,4,5 and HW-155.
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Figure 3.2 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar equivalents
of 1
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Figure 3.3 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar equivalents
of 2
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Figure 3.4 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar equivalents
of 3
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Figure 3.5 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar equivalents
of 4
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Figure 3.6 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar equivalents
of 5
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Figure 3.7 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar
equivalents of 6
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Figure 3.8 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar
equivalents of 7
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Figure 3.9 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar
equivalents of 8
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Figure 3.10 Time-dependent ThT assay of hIAPP1-37 (10µM) and various molar
equivalents of HW-155

The TEM micrographs for hIAPP1-37 revealed a dense network of intertwined
mature fibrils with linear, and thread-like morphology (Figure 3.13) indicating the presence
of hIAPP1-37 amyloid. However, no such fibril was observed in the presence of 2,3,4,5 and
HW-155, indicating a significant prevention of fibril formation by hIAPP1-37.A prevention
of fibril formation by 2, and 5 resulted in the monomers observed in the TEM images.
Likewise, the oligomers seen in 3, 4, and HW-155 were as a result of the inhibition of
formation of mature fibrils.
To visualize the effect of 5 on hIAPP1-37 preformed aggregates, we allowed 10µM
hIAPP1-37 to age for 10h before treatment with a 10 –fold molar excess of 5.AFM showed
a disappearance of mature fibrils (Figure 3.12).However, very few oligomeric hIAPP1-37
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spheres resulting from the disrupted aggregates were observed. This confirms that 5 is able
to disaggregate preformed hIAPP1-37 aggregates.
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PBS control
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Figure 3.11 Time-dependent ThT assay of the disruption of hIAPP1-37 (10µM) preformed
fibrils by 5 (100µM)

Figure 3.12 AFM image the disruption of hIAPP1-37 (10µM) preformed fibrils by 5
(100µM)
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Figure 3.13 TEM images of hIAPP1-37 alone and in the presence of equimolar amount
2,3,4,5, and HW-155.

Based on our findings on the inhibition of hIAPP1-37 fibrillation by 2,3,4,5 and HW155, we further assessed their safety index in mammalian cells by CCK-8 assay. We tested
the toxic effects of 1µM and 5µM concentrations of 2,3,4,5, and HW-155 on NIH-3T3
cells (Figure 3.14). At 1µM concentration, only peptide 2 altered the viability of the cell
(~10% reduction). However, at a peptide concentration of 5µM, peptides 3, 4, 5, and HW155 reduced the cell viability by at least 10%, while peptide 2 showed a significant cell
viability reduction of about 20%.At both concentrations tested, peptide 2 exhibited some
cytotoxic effect on the NIH-3T3 cells.
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Figure 3.14 Effects of peptides 2,3,4,5 and HW-155 on NIH-3T3 cells in CCK-8 cell
viability assay

To study the ability of peptides 2,3,4,5 and HW-155 to modulate the hIAPP1-37
amyloid – induced cytotoxicity, we treated NIH-3T3 cells with hIAPP1-37 (10µM) and 5µM
peptide as described in the general information section. Results showed that cells treated
with only hIAPP1-37 exhibited a significant reduction in survival, whereas, treatment with
5µM concentration of peptides 2,3,4,5 and HW-155 was able to rescue the cells from
hIAPP1-37 amyloid assembly cytotoxicity (Figure 3.15).However, it is noteworthy that
peptides 3,4, and 5 were better at reducing cell death due to hIAPP1-37 amyloid toxicity
than 2 and HW-155.
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Figure 3.15 Evaluation of the potential of peptides 2,3,4,5 and HW-155 to improve the
chances of cell survival in the presence of hIAPP1-37 amyloid.
3.3 Conclusion
Altogether, this study provides experimental support to the dual action of HW-155
in preventing amyloid fibril formation by Aβ36 and hIAPP1-37. We have utilized a simple,
but effective approach for designing potential inhibitors of hIAPP1-37 fibrillation. We have
also demonstrated the ability of HW-155 analogues to effectively disaggregate preformed
hIAPP1-37 fibrils. The truncation/substitution of side chains in HW-155 resulted in
analogues that proved more effective in amyloid prevention, and disaggregation of
preformed hIAPP1-37 amyloid than HW-155. HW-155 as a dual inhibitor compound, does
not only have greater advantages over other known inhibitors of amyloid formation that
only target a specific amyloid system, it also provides a template for the design of potent
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analogues that could be next-generation therapeutic agents for the treatment of Type 2
diabetes mellitus.
3.4 Materials and Methods
Peptides Synthesis
General Information Fmoc –protected α-amino acids and Rink amide resin used for γAApeptide synthesis were purchased from Chem-Impex International,Inc.. All chemicals
and solvents used were purchased from Aldrich or Fisher and were used without further
purification.
γ-AApeptide Monomer Synthesis

Figure 3.16 Synthesis of γ-AApeptide building block/monomeric unit.
Solid Phase Peptide Synthesis Peptides were synthesized on the rink amide resin
(0.6mmol/g) on a Burrell Wrist-action shaker (Figure 3.2).200 mg resin was treated twice
(15 mins each time) with 3ml 20% Piperidine in DMF to deprotect the Fmoc group. The
beads were then washed thrice with 3ml each of DCM and DMF. The desired N-alloc
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protected γ-AApeptide building blocks were prepared (Figure 3.16) and are combined (2
equivalents) with 4 equivalents each of HOBt and DIC in 3ml DMF. The solution was then
added to the deprotected resin and was allowed to react for 4 hours. Ninhydrin test35 was
used to confirm the success of the coupling and depending on the Ninhydrin test result, a
second round of coupling was done. On reaction completion, the beads were washed with
DMF and DCM, followed by a fifteen minutes (15 min) capping reaction with 500uL
Acetic Acid .After capping,the beads were washed and alloc-deprotection reaction was
done by reacting the beads with Pd (PPh3)4 (1 equivalent)and Me2NH BH3 (6 equivalents)
(10 mins each time).The beads were then washed with DCM and DMF, followed by the
reaction of the deprotected beads with acyl chloride (4 equivalents) and DIPEA (6
equivalents) in 3ml DCM for 1h or with the carboxylic acid (4 equivalents), HOBt (8
equivalents), and DIC (8 equivalents) for 6h (x2).
The above steps were repeated to assemble the desired sequence on the resin
(Figure 3.17). After these, the resin was washed and the peptide was cleaved from the resin
with the cocktail: TFA/H2O/TIS (95/2.5/2.5) for 2.5h.The solvent evaporated to obtain the
crude peptide which was analysed and purified on an analytical (1ml/min) and a preparative
(20ml/min) Waters HPLC systems, respectively.5-100% linear gradient of 0.1%
TFA/ACN in 0.1 % TFA/H2O over 50 min was used. The HPLC traces were detected at
215 nm. The products were confirmed by MALDI-TOF MS. The product fractions were
then collected and lyophilized.
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Figure 3.17 Solid Phase synthesis scheme for HW-155,C1 and 1-8.

hIAPP Sample Preparation
This was done according to previously published protocol.24, 38 3.1mg of hIAPP1-37
was dissolved in minimal amount of HFIP (50ul) to remove aggregated hIAPP and the
HFIP was removed over a gentle stream of Nitrogen gas. The process was done twice and
5ml of Milli Q pure water was added to the disaggregated hIAPP film. The solution was
then divided into 25 aliquots of 200µl each. The 25 aliquots were lyophilized and
reconstituted in 800µL of PBS prior to use to obtain a hIAPP stock solution of 40µM.The
stock solution was always sonicated prior to use.
Thioflavin T Fluorescence Assay
Inhibition of hIAPP aggregate formation Different peptide concentrations were made in
PBS (x1, pH 7.4). hIAPP stock solution (40µM) was also prepared as described above. The
peptide, hIAPP and 15µM ThT were added into a 96-well black plate. Equal volume of
hIAPP solution was added into the 96-well black plate to make the final concentration of
hIAPP in each well to be 10µM. Time-dependent fluorescent change was monitored for
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24h by the Biotek Synergy H1 hybrid plate reader at excitation and emission wavelengths
of 435 and 490 nm respectively.
Disruption of preformed aggregates Similar to the protocol described above for the
inhibition studies, hIAPP and ThT were added to PBS in a 96-well black plate and at
concentrations of 10µM and 15µM respectively. Time dependent fluorescent change was
monitored for 10h after which 5ul of peptide was added to make a final peptide
concentration of 100µM.5µl of PBS was also added to control wells. Each test well
containing the peptide has a control well to which equal volume of PBS was added. The
fluorescent change was then monitored for another 12h.
Transmission Electron Microscopy (TEM)
Sample preparation was similar to ThT assay. Sample solution containing 10µM
hIAPP1-37 and 12.5µM of the respective peptide were incubated at 30°C for 24h. 10µL
aliquot of the incubated solution was placed on carbon-coated 200-mesh copper grid. After
10 mins, excess solution was wicked away and the grid was allowed to dry. This is then
followed by the addition of 2% uranyl acetate solution (10µL) which was allowed to float
for 5min.The excess solution was then removed using the blotting paper. The copper grid
was left to dry at room temperature before imaging with FEI Morgagni 268D TEM
operated at 60kV.
Atomic Force Microscopy (AFM)
A droplet (10 µl) of the sample solution is placed on the freshly cleaved mica disk
and let it dry in open air at room temperature. Imaging is performed by Multimode 8 AFM
(Bruker, Santa Barbara, CA) and a Nanoscope V controller in Peak Force quantitative
nanomechanics (QNM) air mode. Standard silicon cantilever probe, FMVA(Bruker), with
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spring constant of 2.8N/m, and tip radius 8nm is used for imaging at room temperature.
Images are acquired at scan rate of 1-1.5 Hz and 256pixel/lines.

Percentage inhibition
The percent inhibition was calculated using the formula below:39
Percent inhibition = 100% - (F in the presence of inhibitor / F in the absence of inhibitor X
100) % where F = the average of the ThT signals at 870, 900, 930, 960 and 990 min. These
time points were chosen because the maximum ThT signals were observed at these points
in the uninhibited hIAPP control experiment.
Cell viability/proliferation assay
The 3T3 cells were seeded in a 96-well flat-bottomed microplate (5000
cells/well) and cultured in 100 μL of growth medium at 37°C and 5% CO 2 for 24 h. The
cell culture medium in each well was then replaced with 100 μL of cell growth medium
containing peptides 2,3,4,5 and HW-155 alone at concentrations of 1μM and 5μM or
5µM peptide with 10µM hIAPP1-37.
After incubation for 24 hours at 37°C, the peptides were washed with PBS three
times. Then, 10 μL of CCK-8 dye and 100 μL of DMEM cell culture medium were added
to each well, and the cells were incubated for another 1.5 hour at 37°C. The absorbance
at 450 nm was measured by a Synergy H1 Hybrid Reader (BioTek, Dallas, TX,
USA).Untreated cells served as controls with 100% viability. The results are presented
as the mean±SD of three measurements.
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Table 3.2 HPLC purities and retention time of peptides 1-8 and HW-155
Peptide

Molecular

Mass Purity (based on Retention

[M+H]+

HPLC) %

Time (min)

Yield (%)

(expected/observed)
1

1048.6845/1048.6747

99.01

17.95

80

2

1048.6845/1048.6746

96.48

17.13

83

3

1000.6845/1000.6750

96.59

16.82

70

4

1048.7209/1048.7217

91.42

17.88

78

5

1048.6845/1048.7781

91.61

17.14

90

6

1033.6736/1033.7318

92.47

21.04

87

7

1014.7001/1014.7594

85.32

16.94

95

8

1033.6736/1033.7430

99.1

20.58

96

HW-

1090.7314/1090.7928

98.98

18.95

75

155
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Figure 3.18 HPLC spectra of peptides 1-8 and HW-155
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Figure 3.19 HPLC spectra of peptides 1-8 and HW-155 continued
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CHAPTER 4 : EVALUATION OF THE SEQUENCE-DEPENDENT AGGREGATION
AND INHIBITORY POTENTIAL OF ISLET AMYLOID POLYPEPTIDE-DERIVED
RETRO-PEPTIDES.
4.1 Introduction
Amyloid fibrillation of proteins and peptides are underlying causes of a wide range of
pathological conditions including Parkinson’s, Alzheimer’s

and Diabetes type II

mellitus(T2DM),to mention a few. These pathological conditions are collectively referred to as
protein misfolding or amyloid diseases, and over fifty (50) distinct human protein misfolding
disorders have been reported.1, 2 Even though the culprit proteins in these disorders are dissimilar
in their primary and tertiary structure, their amyloid fibril morphologies share many similarities in
their structure and chemical properties.3 The production of these fibrils have been implicated in
loss of protein function and most importantly, a gain of toxic function by the aggregated protein.2
Human amylin, also called human Islet Polypeptide Hormone (hIAPP), is a 37-residue
peptide responsible for amyloid formation in Type II diabetes mellitus. hIAPP contains three major
regions,the N-terminal region with probable α-helical propensity especially in membrane
conditions, the aggregation –prone middle region(20-29),which contains the core molecular
recognition sequence and amyloid forming units, and the C-terminal region.4Monomeric hIAPP
exhibit random coil conformation, contains a disulfide bridge between cysteine residues at
positions 2 and 7, and is amidated at the C-terminus. However, some previous reports have shown
evidence that hIAPP monomers may adopt helical conformations.5
The step-wise process of hIAPP amyloid formation includes the self-aggregation of
monomers, leading to the conversion of the protein secondary structure from its random coil native
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state to cross β-sheets. The oligomers formed from this process gradually grow into protofibrils,
which eventually matures into full grown toxic fibrils. While it may be true and generally believed
that the full grown fibrils are very toxic,6-8 evidences have shown that the soluble oligomer may
be more toxic.9-11A good understanding of the fibrillation properties and behaviors of hIAPP could
provide insights for the development of inhibitors that are capable of interrupting the
amyloidogenic process.
To date, sequences derived from the middle region of hIAPP have been reported to show
similar aggregation patterns to the full length hIAPP peptide.4, 12-14 Variations in this region can
significantly impact amyloid formation.15 Among the core amyloid forming motifs of hIAPP,
hIAPP22-29 (NFGAILSS) have been shown to form amyloid fibrils with great similarities to the
full-length peptide.13, 16, 17 Hence, it is frequently studied as a simple model for understanding the
factors regulating amyloid fibrillation.18 Modifications in this region have also shed more light on
the relationship between sequence patterns and amyloidogenic properties. Common modifications
include substitution,12, 18 and incorporation of β-sheet breakers.14, 19-21
In line with the above mentioned modifications, we sought to investigate the effects of
retro-inversion on the fibrillation behavior and morphology of hIAPP22-29.This strategy has been
previously exploited for inhibitor design for Aβ.22 Retro-D- peptides (containing retro-inversoand retro-enantio -isomers of a template peptide) or analogues are obtained by reversing the
assembly pattern of parent or template peptides with a simultaneous substitution of L-amino acids
with D-amino acids (Figure 4.1). Theoretically, the side chain orientation in retro-inversed
peptides are projected in a similar fashion to their parent peptides, except for situations when it is
fixed in special secondary structures.23-25 D-amino acids are the stereoisomers of naturally
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occurring L-amino acids and are considered unnatural. Some prokaryotic organisms produce and
use D-amino acids, but in general D-amino production is during chemical synthesis.26

Figure 4.1 A sample L-peptide and its analogues. An L-peptide (1) sequence has three analogues:
the D-enantiomer (3) with the same sequence, the retro L-peptide (4) with the inverted sequence,
and the retro-inverso D-peptide(2), with all D-amino acids and the inverted sequence. Note that
(1) and (2) have similar side chain positions; one is the retro-inverso sequence of the other. The
same applies to (3) and (4). https://commons.wikimedia.org/wiki/File:L-peptideDpeptideAnalogues.png

In the present study, eight retro-analogues of hIAPP22-29 including four (4) retro-inverso
analogues and four (4) retro-analogues with alternating L and D were designed, and their
aggregation propensity and amyloid morphology were systematically characterized using
transmission electron microscopy (TEM), Thioflavin T (ThT) fluorescence assay, Congo red
Spectrophotometric assay, Kinetic aggregation assay and Circular dichroism (CD).We also
evaluated the inhibitory potential of these peptides on hIAPP amyloid aggregation.
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Table 4.1 Peptide sequences of designed retro-peptides.
Retro - peptides

Sequence

r1

RG-sSlIaGfN-GR

r2

Ac-RG-sSlIaGfN-GR

r3

RG-NfGaIlSs-GR

r4

Ac-RG-NfGaIlSs-GR

r5

rG-nfgailss-Gr

r6

Ac-rG-nfgailss-Gr

r7

rG- ssliaGfn-Gr

r8

Ac-rG- ssliaGfn-Gr

hIAPP22-29

NFGAILSS

4.2 Results and Discussion
In this work, we sought to determine the effect of D-amino acid substitution and retro
inversion on the self-assembly behavior and fibril morphology of peptides derived from hIAPP2229.hIAPP22-29

was previously reported to form fibrils with similar morphological features as the

full length hIAPP1-37.
At first, we investigated the presence of amyloid fiber in our retro-peptides. Since the
peptides were derived from an amyloid-prone region of full length hIAPP1-37,we hypothesized that
they should possess inherent self-aggregation properties. We employed various amyloid-detecting
strategies including fluorophore binding – Congo red and ThT, and kinetic aggregation assay to
verify our hypothesis.
Congo red is an amyloidogenic dye with interesting spectrophotometric properties. In
aqueous solution, its maximum absorption wavelength is 490nm.Congo red is able to bind various
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amyloid morphologies ranging from innocuous soluble monomers to toxic mature fibrils. When
bound to amyloid fibrils that are rich in β-sheet, it assumes an orientation which induces torsional
restrictions with a consequent increase in absorption and a red – shift in the maximum absorption
from 490nm to 540nm.27 We observed a gradual red shift in absorbance maxima for our retropeptides over 43 hours (Figure 4.2,Figure 4.3, and Figure 4.4).This indicates the presence of some
amyloid fibers, most especially in peptides comprising alternating L- and D-amino acids.
However, this red-shift is accompanied by an increase in absorption in r1, r8, r2, and r4.
In order to fully understand the aggregation potential of the various retro-peptides, and the
effect of chirality on aggregation patterns, we performed a turbidity assay, using hIAPP22-29 as a
control. The turbidity of the peptide solutions was monitored in a kinetic aggregation assay by
monitoring the absorbance at 405nm as a function of time (Figure 4.10). hIAPP22-29 displayed
higher absorption, which is indicative of the presence of amyloid. Retro-peptides r5, and r7
exhibited a nucleation-dependent aggregation mechanism while r6, displayed a seeded
aggregation kinetics with a maximum absorption similar to hIAPP22-29.However, hIAPP22-29 is
non-nucleation-dependent. We observed that the retro-inverso peptides r5, r6, r7 and, r8
consisting mainly of D-amino acids showed a higher aggregation potential than peptides
comprising alternating L- and D- amino acids.
Amyloid formation kinetics is a multi-step process comprising many distinctive features
including a lag phase, rapid growth/elongation phase and steady state/equilibrium phase. In a bid
to confirm our results on Kinetic aggregation and Congo red assays, we performed Thioflavin T
fluorescence assay to assess the time-dependence of the aggregation of the retro-peptides.
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The curve obtained for the ThT assay for the retro-peptides showed that hIAPP22-29, r5 and r6
displayed a seeded aggregation kinetics consisting of a short elongation phase leading to the steady
state. hIAPP22-29 showed a higher fluorescent signal than the retro-peptides (Figure 4.5)
Amyloid fibrils consist majorly of β-sheet conformation, hence, UV Circular Dichroism
studies proves useful in determination of the secondary structure of the retro-peptides.A CD signal
around 195nm typically indicates random coil. The signal is negative if it’s due to L-amino acids
and positive for D-amino acids.28 The presence of a maximum and minimum near 195nm and 215
nm respectively signals the presence of a β-sheet. As seen in Figure 4.7, the spectra acquired for
peptides r1 and r2 revealed that both retropeptides have some β-character, with a characteristic
maximum around 200nm and a corresponding minimum at 220nm.r1 and r2 are composed of
alternating units of L- and D- amino acids in a retroinversed arrangement, and an acetylated Nterminus in r2.Surprisingly,r3 and r4 comprising of alternating units of L- and D-amino acids, but
with no retro inversion, exhibited characteristic β-sheets spectra with maxima around 200nm and
minima of 220nm(Figure 4.7).Peptides r5,r6,r7 and r8,which are all D-peptides displayed positive
signals around 200nm(Figure 4.8 and Figure 4.9).This is very typical unstructured conformers
termed random coils. The CD result corroborates previous findings that d-amino acids possess
inherent secondary structure destabilizing properties.29
Having confirmed the amyloidogenic potential of our designed retro-peptides, we decided
to investigate the morphological features of the aggregates formed. We obtained TEM micrographs
of all our retropeptides and hIAPP22-29.In line with previous reports, hIAPP22-29 formed mature
fibrillary bundles similar to full length hIAPP1-37 (Figure 4.6).13,

16, 17

r1 formed amorphous

aggregates while r2 ,r3, and r4 formed protofibrillar structures(Figure 4.6),however, hIAPP
monomers were seen in r5, r6 and r8.
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Encouraged by these results, we proceeded to evaluate the possibility of inhibition of
hIAPP1-37 amyloid fibrillation by our designed peptides, using Thioflavin T assay. 0.6-,2.5-, and
10-fold molar excesses of peptides r1 – r8,15µM ThT and 10µM hIAPP1-37 were added to sample
wells(black 96-well plates), and the relative rise in fluorescent intensity was recorded. The
measurement was done in duplicates. r1 exhibited a dose-dependent relationship, in which the
lowest suppression of fluorescent signal was observed with 10-fold molar excess of peptide.r5 is
suspected to promote aggregation due to an increase in the observed fluorescence signal .At all
concentrations tested,r5 showed similar or higher fluorescent signal than hIAPP1-37.Results also
revealed r6 and r7 inhibited hIAPP1-37 fibril formation at 10-fold and 0.6-fold molar excess
respectively.r2 also displayed some inhibitory effect

at 2.5- and 0.6-fold molar

excesses,whereas,r3 showed moderate inhibition at all peptide concentrations tested.r8 exhibited
weak inhibition at 2.5-fold molar excess and a strong inhibitory effect at 10- and 0.6-fold molar
excess.At 10- and 2.5-fold molar excesses, r4 also showed strong inhibitory effect. Contrary to
previous reports,hIAPP22-29 promoted aggregation at all concentrations tested13

59

0.20

r1(1mM)
r2 (1mM)
r3 (1mM)
r4 (1mM)
r5 (1mM)
r6 (1mM)
r7 (1mM)
r8 (1mM)
hIAPP22-29 (1mM)
Congo Red (20µM)

0.18

Absobance (a.u.)

0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
400

450

500

550

600

650

700

Wavelength (nm)
r1

Figure 4.2 Congo
r2 red spectra of retro-peptides at time t = 0h
r3
r4
r5
r6
r7
r8
hIAPP22-29
Congo Red

0.18
0.16

r1 (1mM)
r2 (1mM)
r3 (1mM)
r4 (1mM)
r5 (1mM)
r6 (1mM)
r7 (1mM)
r8 (1mM)
hIAPP22-29 (1mM)

Absorbance (a.u)

0.14

Congo Red (20µM)

0.12
0.10
0.08
0.06
0.04
0.02
400

450

500

550

600

650

Wavelength (nm)
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Figure 4.5 ThT assay for aggregation of retro-peptides
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Figure 4.7 CD spectra of peptides consisting of alternating L- and D-amino acid units
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Figure 4.10 Kinetic aggregation assay for all peptides.
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Figure 4.11ThT inhibition assay for r1.
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Figure 4.12 ThT inhibition assay for r2.
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Figure 4.13 ThT inhibition assay for r3.
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Figure 4.14 ThT inhibition assay for r4.

66

1400

1600

r5 (100µM)
r5 (25µM)
r5 (6.25µM)
hIAPP1-37 (10µM)

50000

Fluorescence (a.u.)

40000

30000

20000

10000

0
0

200

400

600

800

1000

1200

1400

1600

Time (min)

Figure 4.15 ThT inhibition assay for r5.
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Figure 4.16 ThT inhibition assay for r6.
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Figure 4.17 ThT inhibition assay for r7.
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Figure 4.18 ThT inhibition assay for r8.
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Figure 4.19 ThT inhibition assay for hIAPP22-29.

4.3 Conclusion
In this study, we evaluated the effects of alternating L- and D-amino acids, retro-inversion
and all D-peptides on the self-aggregation potential and amyloid morphology of peptides derived
from hIAPP22-29.Our results showed the complete incorporation of D-peptides in hIAPP22-29 (all
D-peptides) dramatically changed the secondary structure from the known cross β-sheet to random
coil, whereas ,alternating L- and D-amino acids did not significantly alter the β-sheet
conformation.we also observed that aggregation behavior is strictly dependent on the nature and
chirality of constituent amino acids rather than N-terminus acetyl capping.
We anticipate that this strategy may provide a template for the understanding of different amyloid
systems, thereby providing insights into the design of novel inhibitors of amyloid aggregation for
various amyloidogenic diseases.
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4.4 General information
Peptide Synthesis
All peptides used in this study were synthesized by the standard Fmoc-based solid phase
peptide synthesis protocol using the Burrell Wrist-Action shaker. All Fmoc protected α-L-amino
acids,α-D-amino acids, and Rink amide resin (0.7mmol/g, 200-400 mesh) were purchased from
Chem-Impex International, Inc. All other Solvents and reagents were purchased from either Sigma
Aldrich or Fisher Scientific and used without further purification.
For each amino acid coupling, 2 equivalents of Fmoc-amino acid, 4equivalents each of
DIC and HOBt were used and the coupling cycle was repeated, followed by capping with 1
equivalent of acetic anhydride and 2 equivalents of pyridine. Fmoc-deprotection was done with
20%piperidine in DMF.The final peptide was cleaved from the resin using a cleavage
cocktail:95%TFA,2.5%TIS,2.5%Water for 3h.TFA was removed by evaporation and the crude
peptide was dissolved in acetonitrile and water. The peptides were analyzed and purified on a
Waters Breeze 2 HPLC System, and then lyophilized on a Labconco Lyophilizer

Congo red binding assay.
Congo red was dissolved in PBS buffer (X 1) to make a stock solution of 100µM.The
stock solution was sonicated and filtered through a 0.4micron filter membrane to remove any
insoluble aggregate. 20µM Congo red solution was then incubated with 1mM retro-peptides in
duplicate wells in a clear 96-well plate for 30 minutes at room temperature before measurement.
The absorption spectra was acquired at a wavelength range of 400nm – 700nm using a Biotek
Synergy H1 hybrid plate reader. The reaction solution in each well was mixed with a pipette before
measurement.
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Circular Dichroism studies.
Circular dichroism (CD) spectra were measured on an Aviv 215 circular dichroism
spectrometer using a 1 nm bandwidth and 1nm step resolution from 200 to 260nm at 25°C. 3 scans
were averaged for each sample. Control water blank scans were run, averaged and then subtracted
from the sample spectra. Retro-peptide solutions were prepared in water to a final concentration
of 200µM and allowed to age for 5 days at 37°C.The samples were loaded in a 1mm path length
quartz cell, and the CD spectra were acquired with an averaging time of 1s, Settling time of 0.333s
and multi-scan wait time of 1s.The data unit was converted from machine units (millidegree, θ)
into mean residue ellipticity [θ].Mean Residue Ellipticity [θ] (deg.cm2.dmol-1) was calculated
using the equation:
[θ] = θobs / (p x c x 10 x n)
Where θobs is the measured ellipticity in millidegrees, while p is the path length in centimeter, n is
the number of side chains and c is the concentration of the peptide in Molar.
Thioflavin T Fluorescence Assay
Detection of amyloid fiber 1mM peptide concentrations were incubated with 15µM ThT in
duplicate wells in a 96-well black plate at a total volume of 100µL. Time-dependent fluorescent
change was monitored for 24h by the Biotek Synergy H1 hybrid plate reader at excitation and
emission wavelengths of 435 and 490 nm respectively.
Inhibition of hIAPP aggregate formation Different peptide concentrations were made in PBS (x1,
pH 7.4). hIAPP stock solution (40µM) was also prepared as described above. The peptide, hIAPP
and 15µM ThT were added into a 96-well black plate. Each reaction solution was duplicated. Equal
volume of hIAPP solution was added into the 96-well black plate to make the final concentration
of hIAPP in each well to be 10µM. Time-dependent fluorescent change was monitored for 24h by
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the Biotek Synergy H1 hybrid plate reader at excitation and emission wavelengths of 435 and 490
nm respectively
Transmission Electron Microscopy (TEM)
10µLof 1mM retro peptide solution was placed on carbon-coated 200-mesh copper grid.
After 10 mins, excess solution was wicked away and the grid was allowed to dry. This is then
followed by the addition of 2% uranyl acetate solution (10µL) which was allowed to float for
5min.The excess solution was then removed using the blotting paper. The copper grid was left to
dry at room temperature before imaging with FEI Morgagni 268D TEM operated at 60kV.
Kinetic aggregation assay
Freshly prepared 3mM stock of retro-peptides were used in the assay. The stock solution
was sonicated and a volume equivalent to ImM retro-peptide was added to clear 96-well plate.
PBS (X1) buffer was added to make the total volume 100µL. The absorption spectra was acquired
for 3h 30min at 30 min interval, and at a wavelength of 405nm, using a Biotek Synergy H1 hybrid
plate reader.
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Table 4.2 Molecular weight of peptides and their percent yield.
Peptide

Molecular

Mass Yield (%)

[M+H]+
(expected/observed)
r1

1233.6738/1233.8107

90

r2

1275.6844/1275.8912

89

r3

1233.6738/1233.8312

92

r4

1275.6844/1275.7228

91

r5

1233.6738/1233.8624

89

r6

1275.6844/1275.8861

93

r7

1233.6738/1233.7389

90

r8

1275.6844/1275.7449

95
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CHAPTER 5 : DEVELOPMENT OF POTENT CHEMICAL PROBES TARGETING
MPP8-H3K9ME INTERACTION.
5.1 Introduction
Cancer is a process of multistep cellular transformation, which consequently lead to
abnormal and uncontrolled cell growth.1 It is mostly characterized by a series of alterations in the
genome and epigenetic network. In higher organisms, the epigenetic network can undergo four
major modifications including chromatin remodeling, microRNAs, DNA methylation and histones
posttranslational

modifications(acetylation,

methylation,

ubiquitination,

phosphorylation,

sumoylation and so on).2Being a major player in the regulation of the chromatin, histone octamers
wrapped with147 base pairs of DNA, forming the nucleosome. The nucleosome is also subjected
to various post-translational modifications(PTM) such as acetylation and methylation.3These
posttranslational modifications are collectively known as the histone code which is identified by
histone “PTM-reader” protein complexes.4-6
Over the past few decades, lysine methylation of histone tails has attracted tremendous
attention in drug discovery research.7, 8 Histone methylation mostly occurs on Lysine and Arginine
residues and can be easily identified by effector protein complexes bearing different binding
domains for methylated histones. Previous studies have reported some of these binding motifs
including chromodomain, tudor domain, WD40 repeat domain, MBT domain PHD fingers and
ankyrin-repeats domain, PWWP domain and chromobarrel domain.9-17 The common code for
recognition by these domains is the coordination of methylated lysine residue via a conserved
aromatic cage. The first identified example of the chromodomain binding motif was in Drosophia
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melanogaster namely heterochromatin protein-1(HP-1) and Polycomb. The HP-1 proteins
identifies H3K9me (histone 3 that is methylated at Lysine 9) through its N-terminal domain. The
Polycomb chromodomain recognizes H3K27me (Histone 3 that is methylated at Lysine at position
27).18-20
Recently, more research efforts has been invested in understanding the diverse function of
H3K9 methylation and identifying more H3K9me-binding chromodomain. MPP8 (M-Phase
Phosphoprotein 8) has been identified and characterized as a novel methyl-H3K9 binding
protein.21, 22 Using their chromodomain, MPP8 binds tri- and di-methylated lysines 9 on histone
3.MPP8 level is elevated in several human primary tumor tissues, while knockdown of MPP8 in
metastatic tumor cells leads to a regain of epithelial characteristics accompanied by a significant
reduction of cell motility and invasiveness, suggesting that MPP8 contributes to EMT and tumor
malignant progression. Mechanistic characterization revealed that MPP8 represses transcription of
E-cadherin by directly binding to methyl-H3K9 marks on the promoter of this key EMT regulator.
Based on the importance of methyl-H3K9 binding by MPP8 in E-cadherin gene silencing
and EMT as well as the potential druggability of its “cavity insertion” binding mode, we
hypothesized that specifically inhibiting MPP8-H3K9me interaction could have therapeutic value
in cancer treatment. To explore this possibility, we developed several chemical probes, among
which two compounds displayed potential to antagonize methyl-H3K9 binding by MPP8 in our
initial characterization.
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Figure 5.1 Peptides designed to disrupt H3K9me3-MPP8 interaction (PJ-164-1 – PJ-164-8)
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Figure 5.2 Peptides designed to disrupt H3K9me3-MPP8 interaction (PJ-164-9 – PJ-164-17)
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Figure 5.3 Western blot from cell fractionation studies (PJ-164-13 – PJ-164-17).
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Figure 5.4 Structure of designed cell-penetrating and cyclic peptides.

5.2 Results and Discussion
Because EMT is very important in converting early stage tumors into invasive
malignancies,23 and a major obstacle to successful anti-cancer therapy, previous works suggest
that blocking MPP8-H3K9me interactions could have potential therapeutic value. The crystal
structure of MPP8/H3K9me3 complex showed that the major interaction points are on K9me3 in
the aromatic cage of MPP8 chromodomain,22, 24 including side chain N-CH3 groups projected
toward the three rings, dimethyl group toward Asp87, and trimethyl group to the open side of the
cage. There are some other residues from H3, which have direct interactions with MPP8, including
Gln5, Thr6, Ala7 and Arg8.22, 24 Based on these reported structural data and the predicted relatively
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high druggability of chromodomain among different methylated lysine binding motifs,25 we
designed and synthesized 24 compounds (Figure 5.1, Figure 5.2, Figure 5.4, and Figure 5.5) which
are expected to reproduce the hydrophobic and charged interactions described and thus bind to
the aromatic cage of MPP8 chromodomain.
The design of these compounds was based on the core binding region of histone 3(H3),
5

QTARKS10.

Figure 5.5 Structure of designed cyclic peptides.
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Figure 5.6 Western blot of cell fractionation assay for peptides PJ 164-18 – PJ 164-24.

This site contains Lysine 9 (K9), which is one of the preferential methylation sites for
histone 3.We introduced various modifications on Lysine 9 including methylation (di-and trimethylation) ,acetylation(di- ,and tri-acetylation),or a combination of both.
At first, we assessed the antagonistic effects of our designed alkylated lysine variants on
H3K9me-MPP8 interaction,using cell fractionation assay followed by western blot analysis.
Myc-MPP8-wt ot W80A was first expressed in 293T cells. Cell fractionation was then performed
on the transfected cells and cytoplasmic (cyto),nuclear extract (NE) and Nuclear pellet (NP)
fractions were collected by a previously described protocol.26Because the localization of MPP8
in the cell is in the Chromatin-bound Nuclear Pellet fraction (NP),the potency of the compounds
is strongly correlated to their ability to dissociate MPP8 from the NP into the NE.21
The western blot of the cell fractionation assay for our first set of designed compounds
revealed that compounds PJ-164-1, PJ-164-8, PJ-164-11, and PJ-164-12 were able to dislodge
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MPP8 from the nuclear pellet into the nuclear extract (Figure 5.3 and Figure 5.6). This implies that
these compounds could compete for MPP8 binding with the wild type H3K9me.
Encouraged by our initial attempt, we further modified our design to include the cyclic
variants of active compounds and we added some arginine residues to the N-terminus to enhance
cell penetration. Interestingly, compounds PJ-164-18, PJ-164-19, PJ-164-21 and PJ-164-24 were
also able to increase the band intensity due to its interaction with MPP8 (Figure 5.6).
5.3 Conclusion
Modulation of H3K9me3 signalling with small molecules has been a subject of intense
research. Inhibitors that could antagonize the methyl reading function of MPP8 may be next
generation anti-cancer agents.
5.4 General information
Peptide Synthesis
All peptides used in this study were synthesized by the standard Fmoc-based solid phase
peptide synthesis protocol using the Burrell Wrist-Action shaker. All Fmoc protected α-L-amino
acids, and Rink amide resin (0.7mmol/g, 200-400 mesh) and 2-Chlorotrityl chloride resin (0.98
mmol/g, 100-200 mesh) were purchased from Chem-Impex International, Inc. All other Solvents
and reagents were purchased from either Sigma Aldrich or Fisher Scientific and used without
further purification.
For each amino acid coupling, 2 equivalents of Fmoc-amino acid, 4equivalents each of
DIC and HOBt were used and the coupling cycle was repeated, followed by capping with 1
equivalent of acetic anhydride and 2 equivalents of pyridine. Fmoc-deprotection was done with
20%piperidine in DMF. The final peptide was cleaved from the resin using a cleavage
cocktail:95%TFA,2.5%TIS,2.5%Water for 3h.TFA was removed by evaporation and the crude
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peptide was dissolved in acetonitrile and water. The peptides were analyzed and purified on a
Waters Breeze 2 HPLC System, and then lyophilized on a Labconco Lyophilizer
For cyclic peptides, Fmoc-Cys (Trt)-OH was added to the N- and C- termini during
synthesis. Cyclization of the fully deprotected lyophilized peptide was achieved in solutionH2O/Acetonitrile (1:1) with 2 equivalents of N-Chlorosuccinimide (NCS).27 The reaction was
allowed to stir for 15mins and then lyophilized.
For peptides synthesized on 2-chlorotrityl chloride resin, 2 equivalents of the second Fmocamino acid residue (synthesis starts at the C-terminus), and 6 equivalents each of DIPEA were
reacted in DCM for 2 hours, followed by Fmoc-deprotection. The next amino acid was then added
and the cycle described above was repeated to achieve the synthesis of the desired sequence. After
capping, the cleavage cocktail -Acetic acid/Trifluoroethanol/DCM in 1:1:8 ratio was added and
the peptidyl- resin was allowed to shake for 2h after which the peptide solution was concentrated
by vacuum and Acetic acid was removed by co-evaporation with hexane. By using this strategy,
the protection group on the side chains are preserved for further coupling reactions in solution.
To obtain the desired complete sequence for peptides synthesized on Chlorotrityl chloride
resin, we converted the C-terminus to a methyl ester of Serine. The protected peptide obtained
after evaporation (1 eq.) and H-Ser-(OtBu)-OMe. HCl (1.2 eq.) were dissolved in 10ml DMF.
DIPEA (2.2 eq.) and TBTU (1.3 eq.) were added to the stirring solution .28The reaction was
allowed to stir for 2h at room temperature. The reaction was then diluted with brine and extracted
with EtOAc. The organic layer was further washed with brine two more times and the then dried
over Sodium Sulfate. The solvent was removed by vacuum evaporation and the residue was
redissolved in a 95:2.5:2.5 mixture of TFA /TIS/H2O to deprotect all side chain groups.
Deprotection reaction was allowed to run for 2h and volatiles were removed under reduced
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pressure and the crude peptide was dissolved in acetonitrile and water. The peptides were analyzed
and purified on a Waters Breeze 2 HPLC System by gradient elution (0.1% TFA in H2O, 0.1%
TFA in Acetonitrile) and then lyophilized on a Labconco Lyophilizer
Synthesis of Building Blocks
Synthesis of Nα -Fmoc-Nε –diethyl-Lysine (5b)
Compound 5a (2.5g, 5.34 mmol) was dissolved in TFA (20mL) at 0°C and was stirred for
3h at room temperature. TFA was then evaporated and the residue was dissolved in MeOH (50
mL) and stirred on ice bath. Acetaldehyde (3.051mL, 54.32 mmol) was added. After 15 mins,
NaCNBH3 (1.28g, 20.37 mmol) was added and allowed to stir for another 15 mins. After 15 mins,
Acetaldehyde and NaCNBH3 were added again and the reaction mixture was stirred for 2h.TLC
was done in MeOH/H2O (95:5) and a Rf ~ 0.3 confirmed the completion of the reaction. The
reaction was acidified with 1M HCl to adjust the pH to about 3 and was then purified with silica
gel column using Chloroform/MeOH (19/1, v/v) as eluent. The pure product (5b, 2.2g) was
obtained after removal of solvent by vacuum evaporation.
Synthesis of Nα -Fmoc-N, N –diethyl-N-methyl Lysine (5c)
Compound 5b (1.0g, 2.4 mmol) was dissolved in ethanol (10mL) and was stirred at room
temperature.NaHCO3 (0.63g, 7.2 mmol) and CH3I (733µL, 12.0 mmol) were added and the
reaction mixture was sealed and stirred for 2days.Reaction was monitored by TLC (MeOH/DCM
1:7; Rf ~ 0.1). Purification was done with silica gel column using Chloroform/MeOH (19/1, v/v)
as eluent. The pure product (5c, 0.3g) was obtained after removal of solvent by vacuum
evaporation.
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Synthesis of Nα -Fmoc-Nε –Dimethyl-Lysine (5d)29, 30
Compound 5a (2.5g, 5.34 mmol) was dissolved in TFA (20mL) at 0°C and was stirred for
3h at room temperature. TFA was then evaporated and the residue was dissolved in MeOH (50
mL) and stirred on ice bath.37% aqueous Formaldehyde (1.167mL, 14.95 mmol) was added. After
15 mins, NaCNBH3 (1.28g, 20.37 mmol) was added. And allowed to stir for another 15 mins.
After 15 mins, Formaldehyde and NaCNBH3 were added again and the reaction mixture was
stirred for 2h.TLC was done in MeOH/H2O (95:5) and a Rf ~ 0.4 confirmed the completion of the
reaction. The reaction was acidified with 1M HCl to adjust the pH to about 3 and was then purified
with silica gel column using Chloroform/MeOH (19/1, v/v) as eluent. The pure product (5d, 2.0g)
was obtained after removal of solvent by vacuum evaporation.

Figure 5.7 Synthetic scheme for the reductive alkylation of Lysine.
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Synthesis of Nα -Fmoc-Nε –Trimethyl-Lysine (5e)29, 30
Compound 5d (1.0g, 2.5 mmol) was dissolved in ethanol (10mL) and was stirred at room
temperature.NaHCO3 (0.63g, 7.5 mmol) and CH3I (780µL,12.5 mmol) were added and the
reaction mixture was sealed and stirred for 2days.Reaction was monitored by TLC (MeOH/DCM
1:7; Rf ~ 0.2). Purification was done with silica gel column using Chloroform/MeOH (19/1, v/v)
as eluent. The pure product (5e, 0.6g) was obtained after removal of solvent by vacuum
evaporation.
Cell fractionation assay
Myc-MPP8-wt or W80A was expressed in 293T cells and the transfected cells were
fractionated into cytoplasmic extract (cyto), nuclear extract (NE) and nuclear pellet (NP) with a
Dounce homogenizer as was previously described.21, 26 The different compounds were dissolved
in DMSO at a concentration of 10mM and were included during the procedure to a final test
concentration of 20µM.The presence of MPP8 in different fractions was then analyzed by western
blot. Lysis buffer was used as a control.
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CHAPTER 6 : CONCLUSION AND FUTURE OUTLOOK
In this chapter, we will be providing a summary of all the projects and their possible future
outlook. We also suggest a way forward for the design of inhibitors of protein-protein interactions
in pathological conditions.
An interesting inference from all our studies is a confirmation of the notion of hotspot
residues. We have demonstrated that a peptide can be completely changed or modified (except for
the position of contact residues), and still retain its minimal function. We have also shown that
peptide mimics bearing groups that mimic the functionality of the natural peptide or protein
exhibited equal or better activity than the template peptide. For instance, our designed
peptidomimetic for HIV-1 fusion inhibition showed better or equal antiviral activity, despite the
modifications introduced. However, there is the need to evaluate the effects of varying the
modification point along the length of the template peptide. This will help us to evaluate how
substitution at those points could modulate the activity of the resulting peptide .This will also
provide better structural insights to the design of potent inhibitors and could provide a template
for the design of antiviral agents. Also, this strategy could be adapted for other viral systems with
similar mode of entry and infection mechanisms.
Talking about the amyloid system, many reported and ongoing research have demonstrated
the adoption of same or similar proven strategies across various amyloid systems .For instance,
many inhibitors of amyloid fibril formation have been derived from the amyloid foming units,
peptide segments, and full length peptide of amyloidogenic proteins, while many others are from
89

rational design. Although, some dual inhibitors have been discovered through fortuitous means,
not many compounds have been developed for dual-action against multiple amyloid systems.
Despite the lack of sequence homology in the amyloid forming units of different amyloidogenic
proteins, there are great similarities in the morphological features of their amyloid fibers. This
implies that intramolecular interactions which promote cross-β-sheet assembly are a major driving
force of aggregation. As such, functionalities that could provide such interactions could be
considered in the design of such multiple/dual-acting amyloid inhibitor.
Together, these works reveal design patterns and provide deeper insights for the advancement of
drug discovery.
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